INFLUENCE OF INTERFERON INDUCER (CYCLOPHERON) ON NONSPECIFIC AND HUMORAL IMMUNITY FACTORS IN BRONCHIAL ASTHMA IN CHILDREN

Abstract

Bronchial asthma (BA) remains one of the most pressing problems in modern pediatrics. The incidence of this pathology is increasing annually and, according to WHO, about 300 million people in the world suffer from asthma. Despite the recent advances in the diagnosis and treatment of asthma, complete control over the course of asthma has failed. The objective of the workwas to evaluate the effect of immunomodulatory therapy on nonspecific and humoral immunity in children with BA by including interferon inducer (cycloferon) in a standard base therapy. There were 120 children with bronchial asthma aged 5 to 14 years, with an average age of (11.6 ± 1.5) years. To determine the diagnosis and effectiveness of therapy used the international classification of diseases of the 10th examination, protocol for the diagnosis and treatment of bronchial asthma in children (order of the Ministry of Health of Ukraine № 767 from 27.12.2005), GINA 2011. The main group (n = 60) included children, who, in addition to basic therapy, received in addition interferon inducer (cycloferon) according to the scheme: 150 mg on 1-, 2-, 4-, 6- and 8-th day of therapy (No. 5) and then 150 mg after 72 hours. (No. 5) (1500 mg total). The comparison group included children (n = 60) who received only basic therapy, depending on the severity of the disease. The control group consisted of 25 healthy children. The level of serum interferon, virus-induced production of interferon-a (IFN-a), mitogen-stimulated production of interferon-g (IFN-g), the level of total serum IgE were determined by the enzyme-linked immunosorbent assay. The phagocytic activity of neutrophils (NG) was evaluated. The circulating immune complexes (CECs), immunoglobulins (Ig) A, M and G in serum were determined by the immunodiffusion reaction method. It was found that the additional use of cycloferon had a corrective effect on phagocytes, which led to an increase in the synthesis of IFN-a and IFN-g, a decrease in the severity of the allergic component due to the decrease in IgE and circulating immune complexes and a normalization of the synthesis of IgA, IgM, IgG with further development of long-term clinical remission of the disease.